Oncology Practice Management Issues

March 2019, Vol 9, No 3

Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer

Chase Doyle

Value-Based Care

Real-world data highlight the significant clinical and economic burden associated with venous thromboembolism (VTE) in patients with cancer. The data come from a study of 12,785 patients hospitalized with acute illnesses, of which 2002 patients had cancer. The results were presented at ASH 2018 and showed that 3.9% of patients with cancer experienced a VTE event requiring rehospitalization—the highest proportion of patients among the study population. Moreover, 28.2% of VTE-related readmissions occurred within the first 30 days of initial hospital discharge. [ Read More ]

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas

Phoebe Starr


Longer-term follow-up of 2 large pivotal clinical trials in B-cell malignancies has demonstrated continuing remissions after chimeric antigen ­receptor (CAR) T-cell therapy: the ELIANA study in pediatric patients and young adults with relapsed or refractory B-acute lymphoblastic leukemia (B-ALL) and the JULIET study in adult patients with diffuse large B-cell lymphoma (DLBCL). Both updates were presented at a press conference at ASH 2018. [ Read More ]

Atezolizumab/Nab-Paclitaxel of No Benefit in PD-L1–Negative Triple-Negative Breast Cancer

Phoebe Starr

Breast Cancer

Triple-negative breast cancer (TNBC) is considered one of the most difficult breast cancers to treat, with few therapeutic options. In an overall analysis of the phase 3 IMpassion130 trial, investigators showed that using the checkpoint inhibitor atezolizumab (Tecentriq), a PD-L1 inhibitor, with nab-paclitaxel (Abraxane) chemotherapy improved disease-free survival (DFS) and overall survival (OS) in patients with advanced or metastatic TNBC compared with placebo plus nab-paclitaxel. [ Read More ]

T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy

Phoebe Starr

Breast Cancer

The adjuvant use of the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla) led to a clinically meaningful and statistically significant improvement in invasive disease-free survival (ie, survival free of invasive disease or death) compared with trastuzumab (Herceptin) in patients with HER2-­positive early-stage breast cancer and residual invasive disease, despite the use of neoadjuvant chemotherapy plus HER2-­targeted therapy, according to the preliminary results of the phase 3 KATHERINE trial. These findings were reported at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

Imbruvica plus Gazyva Approved as First-line Treatment for CLL/SLL

FDA Approvals, News & Updates, Leukemia, Lymphoma

On January 28, 2019, the FDA approved the combination of ibrutinib (Imbruvica; Pharmacyclics), an oral Bruton’s tyrosine kinase inhibitor, plus obinutuzumab (Gazyva; Genentech), a CD20-directed cytolytic antibody, for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Imbruvica has been previously approved as a single agent for the treatment of adults with CLL or SLL, including those with 17p deletion [del(17p)]. [ Read More ]